Marty Makary

Marty Makary appears in Supercharging a New FDA: Marty Makary on Science, Power & Patients as the FDA commissioner explaining a first-year reform agenda to Dave Friedberg at the JP Morgan Healthcare Conference. The source describes his background as public health, Johns Hopkins faculty work, GI and cancer surgery, healthcare quality, transparency, and hospital price transparency.

Makary’s central role in the source is to join speed and accountability. He argues for FDA Review Modernization, Clinical Trial Continuity, Animal Testing Substitution, Post-Market Drug Surveillance, and a Plausible Mechanism Pathway for bespoke therapies, while also saying that drug safety remains the agency’s top priority.

The episode also makes Makary a public-trust figure. His COVID-era critique, vaccine-schedule discussion, nutrition comments, NIH priorities, and AI/wearables guidance connect him to Medical Dogma Trust Repair, Vaccine Schedule Trust Rebuilding, Root-Cause Public Health Research, and Consumer Health AI Governance.

Connections

• FDA - agency he leads in the source.
• All-In and Dave Friedberg - interview context.
• Johns Hopkins University - professional-background institution named in the source.
• Donald Trump - president the source says offered him the FDA commissioner role after reelection.
• Jay Bhattacharya, NIH, and CDC - public-health reform and vaccine-schedule context.
• Most-Favored-Nation Drug Pricing, Food Additive Regulation, and GLP-1 agonists - policy and chronic-disease branches he discusses.